Immutep Ltd (IMM)

Sydney
Currency in AUD
0.325
+0.010(+3.17%)
Closed
IMM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.3180.333
52 wk Range
0.2300.481
Key Statistics
Edit
Bid/Ask
0.32 / 0.32
Prev. Close
0.325
Open
0.32
Day's Range
0.318-0.333
52 wk Range
0.23-0.481
Volume
1.14M
Average Volume (3m)
2.89M
1-Year Change
-12.88%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMM Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
1.130
Upside
+247.69%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Immutep Ltd Company Profile

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Compare IMM to Peers and Sector

Metrics to compare
IMM
Peers
Sector
Relationship
P/E Ratio
−11.1x−2.8x−0.6x
PEG Ratio
−0.530.000.00
Price/Book
2.5x2.8x2.6x
Price / LTM Sales
123.1x10.1x3.1x
Upside (Analyst Target)
201.6%276.5%55.1%
Fair Value Upside
Unlock−8.3%9.2%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.130

(+247.69% Upside)

Earnings

Latest Release
Nov 27, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Immutep (IMM) Stock Price Today?

The Immutep stock price today is 0.325

What Stock Exchange Does Immutep Trade On?

Immutep is listed and trades on the Sydney stock exchange.

What Is the Stock Symbol for Immutep?

The stock symbol for Immutep is "IMM."

What Is the Immutep Market Cap?

As of today, Immutep market cap is 473.07M.

What is Immutep Earnings Per Share?

The Immutep EPS is -0.036.

What Is the Next Immutep Earnings Date?

Immutep will release its next earnings report on 19 Feb 2025.

From a Technical Analysis Perspective, Is IMM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.